Filing Flows › Healthequity (HQY) › R&D spending
Healthequity (HQY) R&D spending by quarter
Healthequity's R&D spending was $73.9M in Q2 FY27 (second quarter fiscal 2027), +9% from Q1 FY27. Over the last 7 quarters it ranged from $61.4M (Q1 FY26) to $73.9M (Q2 FY27).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 FY27 | $73.9M | +9% | +14% |
| Q1 FY27 | $67.8M | -4% | +10% |
| Q4 FY26 | $70.4M | +7% | +9% |
| Q3 FY26 | $65.9M | +2% | — |
| Q2 FY26 | $64.8M | +5% | — |
| Q1 FY26 | $61.4M | -5% | — |
| Q4 FY25 | $64.7M | — | — |
Q2 FY27 at a glance
Healthequity, Q2 FY27: revenue $351M (+8% year over year), operating margin 28.1%, net earnings $65.6M, operating cash flow $136M. The chart follows the revenue to costs, profit and cash.
Questions
What is Healthequity's R&D spending?
Healthequity's R&D spending was $73.9M in Q2 FY27 (second quarter fiscal 2027), +9% from Q1 FY27.
How has Healthequity's R&D spending changed?
Over the last 7 quarters it ranged from $61.4M (Q1 FY26) to $73.9M (Q2 FY27).